Targeted drug delivery to the brain using focused ultrasound

Topics in Magnetic Resonance Imaging

Volumn 17, Issue 3, 2006, Pages 209-215

  Kinoshita, Manabu ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Blood brain barrier; Focused ultrasound; Magnetic resonance imaging; Microbubble

Indexed keywords

ANTINEOPLASTIC AGENT; CLAUDIN; CLAUDIN 12; CLAUDIN 2; CLAUDIN 5; FS 069; METHOTREXATE; RECEPTOR ANTIBODY; TF CRM107; TRASTUZUMAB; UNCLASSIFIED DRUG;

BLOOD BRAIN BARRIER; BRAIN; BRAIN METASTASIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; DRUG DELIVERY SYSTEM; GLIOBLASTOMA; HUMAN; MEMBRANE TRANSPORT; MICROBUBBLE; NONHUMAN; PRIORITY JOURNAL; REVIEW; THERMODYNAMICS; TIGHT JUNCTION; TREATMENT OUTCOME; ULTRASOUND TRANSDUCER;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; CONTRAST MEDIA; DRUG DELIVERY SYSTEMS; DRUG THERAPY; MAGNETIC RESONANCE IMAGING; MICE; MICROBUBBLES; RABBITS; RATS; ULTRASONICS;

EID: 34247167626     PISSN: 08993459     EISSN: None     Source Type: Journal    
DOI: 10.1097/RMR.0b013e3180332e79     Document Type: Review

References (47)

1. Abbott NJ, Ronnback L, Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci. 2006;7:41-53.
2. Liebner S, Kniesel U, Kalbacher H, et al. Correlation of tight junction morphology with the expression of tight junction proteins in blood-brain barrier endothelial cells. Eur J Cell Biol. 2000;79:707-717.
3. Nitta T, Hata M, Gotoh S, et al. Size-selective loosening of the blood-brain barrier in claudin-5-deficient mice. J Cell Biol. 2003;161:653-660.
4. Tsukita S, Furuse M, Itoh M. Multifunctional strands in tight junctions. Nat Rev Mol Cell Biol. 2001;2:285-293.
5. Schwarze SR, Ho A, Vocero-Akbani A, et al. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science. 1999;285:1569-1572.
6. Zhang Y, Pardridge WM. Delivery of beta-galactosidase to mouse brain via the blood-brain barrier transferrin receptor. J Pharmacol Exp Ther. 2005;313:1075-1081.
7. Bickel U, Yoshikawa T, Pardridge WM. Delivery of peptides and proteins through the blood-brain barrier. Adv Drug Deliv Rev. 2001;46:247-279.
8. 111In-peptide nucleic acid antisense radiopharmaceuticals and brain drug-targeting technology. J Nucl Med. 2004;45:1766-1775.
9. Zhu C, Zhang Y, Zhang YF, et al. Organ-specific expression of the lacZ gene controlled by the opsin promoter after intravenous gene administration in adult mice. J Gene Med. 2004;6:906-912.
10. Kilic U, Kilic E, Dietz GP, et al. Intravenous TAT-GDNF is protective after focal cerebral ischemia in mice. Stroke. 2003;34:1304-1310.
11. Dietz GP, Valbuena PC, Dietz B, et al. Application of a blood-brain-barrier-penetrating form of GDNF in a mouse model for Parkinson's disease. Brain Res. 2006;1082:61-66.
12. Snyder EL, Meade BR, Dowdy SF. Anti-cancer protein transduction strategies: reconstitution of p27 tumor suppressor function. J Control Release. 2003;91:45-51.
13. Sugioka R, Shimizu S, Funatsu T, et al. BH4-domain peptide from Bcl-xL exerts anti-apoptotic activity in vivo. Oncogene. 2003;22:8432-8440.
14. Doolittle ND, Miner ME, Hall WA, et al. Safety and efficacy of a multicenter study using intraarterial chemotherapy in conjunction with osmotic opening of the blood-brain barrier for the treatment of patients with malignant brain tumors. Cancer. 2000;88:637-647.
15. Kroll RA, Neuwelt EA. Outwitting the blood-brain barrier for therapeutic purposes: osmotic opening and other means. Neurosurgery. 1998;42:1083-1099. discussion 1099-1100.
16. Neuwelt EA, Goldman DL, Dahlborg SA, et al. Primary CNS lymphoma treated with osmotic blood-brain barrier disruption: prolonged survival and preservation of cognitive function. J Clin Oncol. 1991;9:1580-1590.
17. Weaver M, Laske DW. Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) for therapy of malignant gliomas. J Neurooncol. 2003;65:3-13.
18. Laske DW, Youle RJ, Oldfield EH. Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nat Med. 1997;3:1362-1368.
19. Tempany CM, Stewart EA, McDannold N, et al. MR imaging-guided focused ultrasound surgery of uterine leiomyomas: a feasibility study. Radiology. 2003;226:897-905.
20. McDannold N, Tempany CM, Fennessy FM, et al. Uterine leiomyomas: MR imaging-based thermometry and thermal dosimetry during focused ultrasound thermal ablation. Radiology. 2006;240:263-272.
21. Klibanov AL. Microbubble contrast agents: targeted ultrasound imaging and ultrasound-assisted drug-delivery applications. Invest Radiol. 2006;41:354-362.
22. Miller AP, Nanda NC. Contrast echocardiography: new agents. Ultrasound Med Biol. 2004;30:425-434.
23. Gwyther SJ. New imaging techniques in cancer management. Ann Oncol. 2005;16(suppl 2):63-70.
24. Li T, Tachibana K, Kuroki M. Gene transfer with echo-enhanced contrast agents: comparison between Albunex, Optison, and Levovist in mice - initial results. Radiology. 2003;229:423-428.
25. Taniyama Y, Tachibana K, Hiraoka K, et al. Development of safe and efficient novel nonviral gene transfer using ultrasound: enhancement of transfection efficiency of naked plasmid DNA in skeletal muscle. Gene Ther. 2002;9:372-380.
26. Taniyama Y, Tachibana K, Hiraoka K, et al. Local delivery of plasmid DNA into rat carotid artery using ultrasound. Circulation. 2002;105:1233-1239.
27. Kinoshita M, Hynynen K. A novel method for the intracellular delivery of siRNA using microbubble-enhanced focused ultrasound. Biochem Biophys Res Commun. 2005;335:393-399.
28. Kinoshita M, Hynynen K. Intracellular delivery of Bak BH3 peptide by microbubble-enhanced ultrasound. Pharm Res. 2005;22:716-720.
29. Deng CX, Sieling F, Pan H, et al. Ultrasound-induced cell membrane porosity. Ultrasound Med Biol. 2004;30:519-526.
30. Skyba DM, Price RJ, Linka AZ, et al. Direct in vivo visualization of intravascular destruction of microbubbles by ultrasound and its local effects on tissue. Circulation. 1998;98:290-293.
31. Miller DL, Quddus J. Diagnostic ultrasound activation of contrast agent gas bodies induces capillary rupture in mice. Proc Natl Acad Sci U S A. 2000;97:10179-10184.
32. Patrick JT, Nolting MN, Goss SA, et al. Ultrasound and the blood-brain barrier. Adv Exp Med Biol. 1990;267:369-381.
33. Hynynen K, McDannold N, Vykhodtseva N, et al. Noninvasive MR imaging-guided focal opening of the blood-brain barrier in rabbits. Radiology. 2001;220:640-646.
34. Hynynen K, McDannold N, Sheikov NA, et al. Local and reversible blood-brain barrier disruption by noninvasive focused ultrasound at frequencies suitable for trans-skull sonications. Neuroimage. 2005;24:12-20.
35. McDannold N, Vykhodtseva N, Raymond S, et al. MRI-guided targeted blood-brain barrier disruption with focused ultrasound: histological findings in rabbits. Ultrasound Med Biol. 2005;31:1527-1537.
36. Kinoshita M, McDannold N, Jolesz FA, et al. Targeted delivery of antibodies through the blood-brain barrier by MRI-guided focused ultrasound. Biochem Biophys Res Commun. 2006;340:1085-1090.
37. Kinoshita M, McDannold N, Jolesz FA, et al. Noninvasive localized delivery of Herceptin to the mouse brain by MRI-guided focused ultrasound-induced blood-brain barrier disruption. Proc Natl Acad Sci U S A. 2006;103:11719-11723.
38. Sheikov N, McDannold N, Vykhodtseva N, et al. Cellular mechanisms of the blood-brain barrier opening induced by ultrasound in presence of microbubbles. Ultrasound Med Biol. 2004;30:979-989.
39. Raymond SB, Skoch J, Hynynen K, et al. Multiphoton imaging of ultrasound/Optison mediated cerebrovascular effects in vivo. J Cereb Blood Flow Metab. 2006. Epub ahead of print.
40. McDannold N, Vykhodtseva N, Hynynen K. Targeted disruption of the blood-brain barrier with focused ultrasound: association with cavitation activity. Phys Med Biol. 2006;51:793-807.
41. Pegram M, Slamon D. Biological rationale for HER2/neu (c-erbB2) as a target for monoclonal antibody therapy. Semin Oncol. 2000;27:13-19.
42. Baselga J. Clinical trials of single-agent trastuzumab (Herceptin). Semin Oncol. 2000;27:20-26.
43. Rubenstein JL, Combs D, Rosenberg J, et al. Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood. 2003;101:466-468.
44. Pestalozzi BC, Brignoli S. Trastuzumab in CSF. J Clin Oncol. 2000;18:2349-2351.
45. Bendell JC, Domchek SM, Burstein HJ, et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer. 2003;97:2972-2977.
46. Markesbery WR, Brooks WH, Gupta GD, et al. Treatment for patients with cerebral metastases. Arch Neurol. 1978;35:754-756.
47. Hynynen K, Clement GT, McDannold N, et al. 500-Element ultrasound phased array system for noninvasive focal surgery of the brain: a preliminary rabbit study with ex vivo human skulls. Magn Reson Med. 2004;52:100-107.